Nivolumab-Chemotherapy Combo Boosts PFS in cHL, Poised for Standard Use
The N-AVD regimen consisting of nivolumab (Opdivo) with doxorubicin, vinblastine, and dacarbazine, demonstrated superior progression-free survival (PFS) vs BV-AVD (brentuximab vedotin [Adcetris] with doxorubicin, vinblastine, and dacarbazine) in advanced …